BioSpace News Archive

Protect Pharmaceutical Corporation, Inc. “OTC:(PRTT)” announces that after many months of strategic planning and development, the two companies are ready to announce the details of their upcoming merger.

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock.

Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal.

Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test.

T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Patent and Trademark Office has issued patent number 11,326,213.

ClearPoint Neuro, Inc. today congratulates partner PTC Therapeutics for receiving a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending its gene therapy treatment Upstaza™ (eladocagene exuparvovec),

TFF Pharmaceuticals, Inc. announced that President and CEO Glenn Mattes will be virtually participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022.

Ei.Ventures Inc. (“Ei”) today announced an update on the previously announced merger with Mycotopia (OTC: TPIA).

TherapeuticsMD, Inc. today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA.

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.